Levornidazole Disodium Phosphate for Injection — Competitive Intelligence Brief

Levornidazole Disodium Phosphate for Injection (Levornidazole Disodium Phosphate for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitroimidazole antibiotic. Area: Infectious Disease.

marketed Nitroimidazole antibiotic Microbial DNA (non-selective; requires anaerobic reduction) Infectious Disease Small molecule

Target snapshot

Levornidazole Disodium Phosphate for Injection (Levornidazole Disodium Phosphate for Injection) — Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd. Levornidazole is a nitroimidazole antimicrobial that generates reactive oxygen species to damage DNA and disrupt cellular function in anaerobic microorganisms and certain parasites.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levornidazole Disodium Phosphate for Injection TARGET	Levornidazole Disodium Phosphate for Injection	Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd	marketed	Nitroimidazole antibiotic	Microbial DNA (non-selective; requires anaerobic reduction)
Metronidazole (ST14)	Metronidazole (ST14)	National Taiwan University Hospital	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA
Metronidazole (BQ10)	Metronidazole (BQ10)	National Taiwan University Hospital	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA
Metronidazole Suppositories	Metronidazole Suppositories	Dongfang Hospital Beijing University of Chinese Medicine	marketed	Nitroimidazole antibiotic	Bacterial/protozoal DNA
Metronidazole Tablet	Metronidazole Tablet	Appili Therapeutics Inc.	marketed	Nitroimidazole antibiotic	Bacterial and parasitic DNA
Cefazolin and Metronidazole.	Cefazolin and Metronidazole.	The University of Texas Health Science Center, Houston	marketed	Beta-lactam antibiotic and nitroimidazole antibiotic combination	Penicillin-binding proteins (cefazolin); anaerobic bacterial DNA (metronidazole)
ceftriaxone sodium + metronidazole	ceftriaxone sodium + metronidazole	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Beta-lactam antibiotic + nitroimidazole antibiotic combination	Bacterial penicillin-binding proteins (ceftriaxone); anaerobic bacterial DNA (metronidazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitroimidazole antibiotic class)

1. National Taiwan University Hospital · 2 drugs in this class
2. Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd · 2 drugs in this class
3. University of Guarulhos · 2 drugs in this class
4. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
5. LEO Pharma · 1 drug in this class
6. Sherief Abd-Elsalam · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. Appili Therapeutics Inc. · 1 drug in this class
10. bioRASI, LLC · 1 drug in this class